258 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
SGEN Seattle Genetics, Inc. $76.15 $12.09B Downtrend
Article Searches
When markets turn choppy, these stocks will be the first ones hedge funds bail on https://www.cnbc.com/2019/03/01/in-choppy-markets-these-stocks-will-be-the-first-ones-hedge-funds-bail-on.html Mar 01, 2019 - Jefferies' equity strategist Steven DeSanctis warned investors of the darling stocks the most active funds own.
Affimed Lays Out Accelerated Pathway For AFM13 At R&D Day https://seekingalpha.com/article/4242225-affimed-lays-accelerated-pathway-afm13-r-and-d-day?source=feed_sector_healthcare Feb 19, 2019 - AFM13 data at ASH proved deepening and durable for relapsed & refractory Hodgkin's Lymphoma.Data compares favorably to existing salvage therapies and opens the door for accelerated approval.At a R&D d
Seattle Genetics' Adcetris Gets EC Nod for Label Expansion http://www.zacks.com/stock/news/354019/seattle-genetics-adcetris-gets-ec-nod-for-label-expansion?cid=CS-ZC-FT-354019 Feb 12, 2019 - Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.
By Besting Herceptin, The Future Is Bright For MacroGenics https://seekingalpha.com/article/4239967-besting-herceptin-future-bright-macrogenics?source=feed_sector_healthcare Feb 11, 2019 - Margetuximab has blockbuster potential boding well for MacroGenics as the data support initiation of a head to head trial in the first line.Yet again, the analysts were wrong.A wealth of preclinical a
Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark http://www.zacks.com/stock/news/353400/seattle-genetics-sgen-q4-loss-widens-revenues-top-mark?cid=CS-ZC-FT-353400 Feb 08, 2019 - Seattle Genetics (SGEN) incurs wider-than-expected loss in Q4 but rides high on revenue beat.
Seattle Genetics, Inc. 2018 Q4 - Results - Earnings Call Slides https://seekingalpha.com/article/4239476-seattle-genetics-inc-2018-q4-results-earnings-call-slides?source=feed_sector_healthcare Feb 08, 2019 -
Seattle Genetics (SGEN) Q4 2018 Earnings Conference Call Transcript https://www.fool.com/earnings/call-transcripts/2019/02/08/seattle-genetics-sgen-q4-2018-earnings-conference.aspx?source=iedfolrf0000001 Feb 08, 2019 - SGEN earnings call for the period ending December 31, 2018.
The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs http://feeds.benzinga.com/~r/benzinga/~3/6h2fRIXthIU/the-daily-biotech-pulse-big-miss-for-seattle-genetics-hematology-conf Feb 08, 2019 -

The following are top developments in the biotech space over the last 24 hours:

Scaling The Peaks

(Biotech stocks that hit 52-week highs Feb. 7.)

read more

Trump's China Caution Deflates Investors On Edge Over Trade (Wall Street Breakfast Podcast) https://seekingalpha.com/article/4239366-trumps-china-caution-deflates-investors-edge-trade-wall-street-breakfast-podcast?source=feed_all_articles Feb 08, 2019 - Today's Top Stories: Trump's China caution deflates investors on edge over trade; Trump to ban China telecom equipment over cyber threats; and Jeff Bezos accuses National Enquirer of blackmail. If you
Wall Street Breakfast: Trump's China Caution Deflates Investors On Edge Over Trade https://seekingalpha.com/article/4239346-wall-street-breakfast-trumps-china-caution-deflates-investors-edge-trade?source=feed_tag_wall_st_breakfast Feb 08, 2019 - Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes, Stitcher and SoundCloud (click the highlighted links). U.S. stock futures point to additional loss

Pages: 123456...26

Page 1>

Related Companies

Name Exchange Price Mkt Cap
NBIX Neurocrine Biosciences, Inc. NASDAQ $117.38 $10.62B
QGEN Qiagen N.V. NYSE $37.42 $8.5B
QGEN Qiagen N.V. NASDAQ $37.42 $8.5B
BLUE bluebird bio, Inc. NASDAQ $137.25 $7.43B
TECH Bio-Techne Corp NASDAQ $196.8 $7.43B
Sector: Health Care > Industry: Biotechnology: Biological Products (No Diagnostic Substances)
DeepLinks for Seattle Genetics
SGEN - Google Finance https://www.google.com/finance?q=SGEN Industry related info and international coverage Summary News
SGEN - Bloomberg http://www.bloomberg.com/research/stocks/snapshot/snapshot.asp?ticker=SGEN Original news and commentary from Bloomberg Charts Financials with pensions Snapshot Earnings Transactions People Options